Report: Current Stock Reports

FDA lifts partial clinical hold on RVU120 (SEL120) Phase Ib study in acute myeloid leukemia and myelodysplastic syndrome
July 14, 2021

Notifications from persons discharging managerial responsibilities in the Company – Article 19 of MAR
July 13, 2021

Information on the change in the shareholder structure due to execution of the Stock Grant Program in the Company – Art. 69 of the Act on Offerings
July 9, 2021

Correction of the current report No. 22/2021 of July 8, 2021
July 8, 2021

Conclusion of the share donation agreement between the Company and President of the Management Board and main shareholder of the Company in execution of a non-diluting incentive program in the Company
July 8, 2021

Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June, 29 2021
June 30, 2021

Resolutions adopted by the General Shareholders Meeting of Ryvu Therapeutics S.A.
June 30, 2021

Publication of clinical data for phase I RVU120 and phase I/II SEL24 (MEN1703)
June 11, 2021

Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
June 2, 2021

Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Poland
May 28, 2021

Publication of abstract related to SEL24 (MEN1703) program at ASCO Annual Meeting 2021
May 20, 2021

Shareholders controlling at least 5% of the vote at the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A. convened on May 17, 2021
May 17, 2021

Resolutions adopted by the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
May 17, 2021

Information concerning impact of non-diluting incentive program on Company’s financial statements
May 13, 2021

New data from RVU120 and SEL24(MEN1703) programs to be presented at the EHA Congress 2021
May 12, 2021

Declaration of establishing a non-diluting incentive program in the Company for the years 2021-2024
April 20, 2021

Partial Clinical Hold of Phase Ib Clinical Trial of RVU120 (SEL120) by the FDA in Acute Myeloid Leukemia and Myelodysplastic Syndrome
April 8, 2021

Notification from person discharging managerial responsibilities in the Company – Article 19 of MAR
April 8, 2021

Conclusion of the grant agreement with the National Center for Research and Development
March 18, 2021

Ryvu Therapeutics to present recent data from multiple oncology programs at AACR 2021 Virtual Annual Meeting
March 11, 2021